206 related articles for article (PubMed ID: 35718282)
1. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.
Durkee-Shock JR; Keller MD
Ann Allergy Asthma Immunol; 2022 Nov; 129(5):562-571.e1. PubMed ID: 35718282
[TBL] [Abstract][Full Text] [Related]
2. Immune Responses 6 Months After mRNA-1273 COVID-19 Vaccination and the Effect of a Third Vaccination in Patients with Inborn Errors of Immunity.
van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
J Clin Immunol; 2023 Aug; 43(6):1104-1117. PubMed ID: 37231290
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
van Leeuwen LPM; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk F; van Gorp ECM; de Wilt F; Bogers S; Gommers L; Geers D; Bruns AHW; Leavis HL; van Haga JW; Lemkes BA; van der Veen A; de Kruijf-Bazen SFJ; van Paassen P; de Leeuw K; van de Ven AAJM; Verbeek-Menken PH; van Wengen A; Arend SM; Ruten-Budde AJ; van der Ent MW; van Hagen PM; Sanders RW; Grobben M; van der Straten K; Burger JA; Poniman M; Nierkens S; van Gils MJ; de Vries RD; Dalm VASH
J Allergy Clin Immunol; 2022 Jun; 149(6):1949-1957. PubMed ID: 35421449
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.
Göschl L; Mrak D; Grabmeier-Pfistershammer K; Stiasny K; Haslacher H; Schneider L; Deimel T; Kartnig F; Tobudic S; Aletaha D; Burgmann H; Bonelli M; Pickl WF; Förster-Waldl E; Scheinecker C; Vossen MG
Front Immunol; 2022; 13():974987. PubMed ID: 36189225
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
Hagin D; Freund T; Navon M; Halperin T; Adir D; Marom R; Levi I; Benor S; Alcalay Y; Freund NT
J Allergy Clin Immunol; 2021 Sep; 148(3):739-749. PubMed ID: 34087242
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
10. Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19.
Abolhassani H; Delavari S; Landegren N; Shokri S; Bastard P; Du L; Zuo F; Hajebi R; Abolnezhadian F; Iranparast S; Modaresi M; Vosughimotlagh A; Salami F; Aranda-Guillén M; Cobat A; Marcotte H; Zhang SY; Zhang Q; Rezaei N; Casanova JL; Kämpe O; Hammarström L; Pan-Hammarström Q
J Allergy Clin Immunol; 2022 Nov; 150(5):1059-1073. PubMed ID: 36113674
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
13. Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study.
Milito C; Cinetto F; Garzi G; Palladino A; Puca M; Brambilla E; De Vitis C; Costanzo G; Scarpa R; Punziano A; Lagnese G; Del Giacco S; Spadaro G; Quinti I; Firinu D
J Clin Immunol; 2023 Feb; 43(2):299-307. PubMed ID: 36374363
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC; Li YH; Guan XH; Hou LH; Wang WJ; Li JX; Wu SP; Wang BS; Wang Z; Wang L; Jia SY; Jiang HD; Wang L; Jiang T; Hu Y; Gou JB; Xu SB; Xu JJ; Wang XW; Wang W; Chen W
Lancet; 2020 Jun; 395(10240):1845-1854. PubMed ID: 32450106
[TBL] [Abstract][Full Text] [Related]
15. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination.
Salgado Del Riego E; Saiz ML; Corte-Iglesias V; Leoz Gordillo B; Martin-Martin C; Rodríguez-Pérez M; Escudero D; Lopez-Larrea C; Suarez-Alvarez B
Front Immunol; 2022; 13():942192. PubMed ID: 36275696
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against respiratory tract pathogens in primary immune deficiency patients receiving immunoglobulin replacement therapy.
Bayrak Durmaz MS; Yıldız R; Keskin G; Altıner S
Tuberk Toraks; 2024 Mar; 72(1):1-8. PubMed ID: 38676589
[TBL] [Abstract][Full Text] [Related]
17. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus disease 2019 vaccination uptake and hesitancy among Polish patients with inborn errors of immunity, autoinflammatory syndromes, and rheumatic diseases: A multicenter survey.
Więsik-Szewczyk E; Ziętkiewicz M; Będzichowska A; Napiórkowska-Baran K; Matyja-Bednarczyk A; Felis-Giemza A; Jahnz-Różyk K
Front Immunol; 2022; 13():1010899. PubMed ID: 36275663
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]